U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Guidance for Industry: The Use of an Alternate Name for Potassium Chloride in Food Labeling
  1. Search for FDA Guidance Documents


Guidance for Industry: The Use of an Alternate Name for Potassium Chloride in Food Labeling December 2020

Docket Number:
Issued by:
Guidance Issuing Office
Center for Food Safety and Applied Nutrition, Office of Nutrition and Food Labeling

December 2020

The purpose of this guidance is to advise food manufacturers of our intent to exercise enforcement discretion for declaration of the name “potassium salt” in the ingredient statement on food labels as an alternative to the common or usual name “potassium chloride.”

FDA intends to exercise this enforcement discretion to provide industry with greater flexibility when labeling their food products, including those that are formulated to reduce sodium content. This enforcement discretion may result in manufacturers using potassium chloride as a substitute ingredient for some sodium chloride and may lead to reduced sodium intake.

This guidance is consistent with FDA’s Nutrition Innovation Strategy to reduce the burden of chronic disease in the United States through improved nutrition, by empowering consumers with information, and supporting and fostering industry innovation in developing and promoting healthfulness of food options. This guidance is also consistent with FDA’s previous activities to encourage manufacturers to reduce the sodium levels in food products in the interest of public health.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe our current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required.

Download the Guidance

Related Information

Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2019-D-0892.

Back to Top